Details of Disease

General Information of Disease (ID: DISWX7MU)

• Disease Name: Fibrosarcoma
• Synonyms: fibrocytic tumor; fibrocytic tumour; fibrosarcoma (excluding infantile fibrosarcoma); malignant fibromatous neoplasm; fibrosarcoma (disease); fibrosarcoma - not infantile; fibrosarcoma; fibrous tissue neoplasm; fibrosarcoma of soft tissue; fibrosarcoma, malignant
• Definition: MONDO_0018078|MONDO_0006209
• Disease Hierarchy:
  DISSN8XB: Soft tissue sarcoma
  DISWX7MU: Fibrosarcoma
• Disease Identifiers:
  MONDO ID: MONDO_0005164
  MESH ID: D005354
  UMLS CUI: C0016057
  MedGen ID: 5178
  HPO ID: HP:0100244
  Orphanet ID: 2030
  SNOMED CT ID: 53654007

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 34 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ANPEP	TTPHMWB	Limited	Biomarker	[1]
F3	TT38MDJ	Limited	Altered Expression	[2]
NTRK3	TTXABCW	Limited	Biomarker	[3]
PDX1	TT8SGZK	Limited	Biomarker	[4]
RHBDF2	TTH1ZOP	Limited	Altered Expression	[5]
TP53BP1	TTX4UE9	Limited	Biomarker	[6]
CDC123	TT3PRUG	moderate	Altered Expression	[7]
FUS	TTKGYZ9	moderate	Biomarker	[8]
JAK1	TT6DM01	moderate	Altered Expression	[9]
LPA	TTU9LGY	moderate	Biomarker	[10]
LPAR5	TTABCJ6	moderate	Biomarker	[11]
MTAP	TTDBX7N	moderate	Biomarker	[12]
PLG	TTP86E2	moderate	Biomarker	[13]
SDC2	TT5H2F0	moderate	Biomarker	[14]
ANG	TTURHFP	Strong	Biomarker	[15]
CPE	TTXPWO6	Strong	Biomarker	[16]
CXCL11	TTWG0RE	Strong	Altered Expression	[17]
GGH	TTZJRL0	Strong	Altered Expression	[18]
GP6	TTTJUVZ	Strong	Biomarker	[19]
GPI	TT19JIZ	Strong	Biomarker	[20]
HSPG2	TT5UM29	Strong	Biomarker	[21]
LIMK2	TTASMD8	Strong	Altered Expression	[22]
MAP3K1	TTW8TJI	Strong	Altered Expression	[23]
MAP3K20	TTTUZ3O	Strong	Biomarker	[24]
MLANA	TT362RB	Strong	Genetic Variation	[25]
MTF1	TTTQDEO	Strong	Biomarker	[26]
NES	TTHZ752	Strong	Biomarker	[27]
PDGFB	TTQA6SX	Strong	Biomarker	[28]
PDXP	TT9UYG4	Strong	Biomarker	[29]
RALBP1	TTVSRUA	Strong	Altered Expression	[30]
RNMT	TTG45HY	Strong	Biomarker	[31]
SMYD3	TTKLJYX	Strong	Altered Expression	[32]
TNFRSF13C	TT7NJSE	Strong	Altered Expression	[33]
TPSAB1	TTM1TDX	Strong	Altered Expression	[34]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC26A2	DTFSLX5	Strong	Altered Expression	[35]
SLC39A13	DTOTKBS	Strong	Biomarker	[36]

This Disease Is Related to 3 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CHST3	DEQIZP2	Strong	Altered Expression	[37]
HPRT1	DEVXTP5	Strong	Altered Expression	[38]
PGPEP1	DEVDR46	Strong	Altered Expression	[39]

This Disease Is Related to 72 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
EWSR1	OT7SRHV3	Limited	Genetic Variation	[40]
GLIS3	OTBC960E	Limited	Biomarker	[4]
HEATR3	OTB52FZ4	Limited	Biomarker	[41]
RHBDF1	OTCQ7UDS	Limited	Altered Expression	[5]
SLFN5	OTT1AESL	Limited	Altered Expression	[42]
SOX21	OTNT50CC	Limited	Altered Expression	[43]
STK3	OTLNSCQD	Limited	Genetic Variation	[44]
CREG1	OTRHJ8HK	Disputed	Biomarker	[45]
FBLN1	OT5MHHOP	moderate	Biomarker	[46]
FBXW11	OT2A6RLR	moderate	Biomarker	[11]
TFPI2	OTZCRWOR	moderate	Genetic Variation	[47]
TTL	OTSS1CK4	moderate	Biomarker	[48]
TTLL1	OTCE097J	moderate	Biomarker	[48]
ADGRE2	OTUYJVYG	Strong	Altered Expression	[49]
ADGRE5	OTTSB84Q	Strong	Altered Expression	[49]
ALPK1	OTBW6SGD	Strong	Biomarker	[50]
AMFR	OTQRX7LC	Strong	Posttranslational Modification	[51]
ANGPT4	OT881M3K	Strong	Biomarker	[52]
ANGPTL1	OTXIN6V5	Strong	Altered Expression	[15]
ANXA3	OTDD8OI7	Strong	Biomarker	[53]
ARF6	OTVV7KJO	Strong	Biomarker	[54]
ARFIP1	OTXHWO6M	Strong	Biomarker	[55]
ARL4C	OTQ3QNNU	Strong	Biomarker	[50]
CER1	OTTAJJ63	Strong	Biomarker	[56]
CILK1	OTWOYEYP	Strong	Biomarker	[24]
CLDN2	OTRF3D6Y	Strong	Biomarker	[57]
CNBP	OTTGM9NK	Strong	Altered Expression	[58]
COLQ	OT4BHUGQ	Strong	Biomarker	[59]
CREB3L1	OT2JHIHM	Strong	Genetic Variation	[40]
CREB3L2	OT09MHV0	Strong	Biomarker	[8]
DLD	OT378CU9	Strong	Biomarker	[60]
DPYS	OTLTUIVL	Strong	Biomarker	[61]
ETV6	OTCZMG61	Strong	Biomarker	[62]
GDF10	OTEVXGJ7	Strong	Altered Expression	[63]
HCCS	OTQE88BE	Strong	Genetic Variation	[64]
HCLS1	OTX7WGYN	Strong	Altered Expression	[65]
INSL6	OTF8OJQC	Strong	Biomarker	[66]
IRF9	OTK4MYQJ	Strong	Altered Expression	[17]
KCNH4	OTHJ8WTU	Strong	Altered Expression	[67]
KCNH8	OT3I5FLB	Strong	Altered Expression	[67]
KIF5B	OTT34MT8	Strong	Biomarker	[68]
LAMTOR1	OTIBJBW9	Strong	Biomarker	[69]
LRIF1	OTEWN06R	Strong	Biomarker	[66]
MAFB	OTH2N3T8	Strong	Genetic Variation	[70]
MAU2	OTALDF8Q	Strong	Altered Expression	[71]
MCRS1	OT8K2X8P	Strong	Altered Expression	[72]
MINK1	OTKB0RA8	Strong	Biomarker	[73]
MLLT1	OT41UZU5	Strong	Altered Expression	[74]
MMP25	OT3BG37V	Strong	Altered Expression	[75]
MNS1	OT67F3JQ	Strong	Biomarker	[53]
NCKIPSD	OT24UORN	Strong	Biomarker	[76]
NCOA7	OT2CNBOG	Strong	Altered Expression	[77]
NF1	OTC29NHH	Strong	Biomarker	[78]
NR2E1	OTW47GKM	Strong	Altered Expression	[2]
POLD3	OTEQEFQ2	Strong	Biomarker	[79]
PSAP	OTUOEKY7	Strong	Biomarker	[80]
PTGES3	OTPPQWI0	Strong	Biomarker	[81]
RAD17	OT1I93DT	Strong	Altered Expression	[82]
RBM5	OTCBWHHV	Strong	Altered Expression	[83]
REV1	OTHIKICX	Strong	Biomarker	[84]
RIF1	OTPE49OE	Strong	Biomarker	[66]
RRAS	OTBBF28C	Strong	Biomarker	[81]
RSPO2	OT3HHXU0	Strong	Biomarker	[85]
RTL1	OTOT33IM	Strong	Genetic Variation	[25]
SLTM	OT0VRZA6	Strong	Biomarker	[31]
SNRPE	OT18J6E8	Strong	Altered Expression	[86]
STAT2	OTO9G2RZ	Strong	Altered Expression	[17]
SYN1	OTMNPWC1	Strong	Biomarker	[87]
TCL1B	OT4CSO39	Strong	Biomarker	[87]
TIMP2	OT8S1RRP	Strong	Biomarker	[88]
TMED10	OTUXSHH7	Strong	Biomarker	[81]
TBX3	OTM64N7K	Definitive	Biomarker	[89]

References

• [1] Preparation and comparative evaluation of (99m) Tc-HYNIC-cNGR and (99m) Tc-HYNIC-PEG(2) -cNGR as tumor-targeting molecular imaging probes.J Labelled Comp Radiopharm. 2018 Feb;61(2):68-76. doi: 10.1002/jlcr.3585. Epub 2018 Feb 2.
• [2] Tumor cells expressing tissue factor influence the migration of smooth muscle cells in a catalytic activity-dependent way.Can J Physiol Pharmacol. 2009 Sep;87(9):694-701. doi: 10.1139/y09-063.
• [3] Novel NTRK3 Fusions in Fibrosarcomas of Adults.Am J Surg Pathol. 2019 Apr;43(4):523-530. doi: 10.1097/PAS.0000000000001194.
• [4] Emerging roles of GLIS3 in neonatal diabetes, type 1 and type 2 diabetes.J Mol Endocrinol. 2017 Feb;58(2):R73-R85. doi: 10.1530/JME-16-0232. Epub 2016 Nov 29.
• [5] Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17.Sci Signal. 2015 Nov 3;8(401):ra109. doi: 10.1126/scisignal.aac5356.
• [6] Characterizing the DNA damage response in fibrosarcoma stem cells by in-situ cell tracking.Int J Radiat Biol. 2019 Feb;95(2):99-106. doi: 10.1080/09553002.2019.1539879. Epub 2018 Nov 29.
• [7] Small interfering RNA targeting HIF-1 reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro.Strahlenther Onkol. 2011 Apr;187(4):252-9. doi: 10.1007/s00066-011-2167-0. Epub 2011 Mar 25.
• [8] Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group.Am J Surg Pathol. 2007 Sep;31(9):1387-402. doi: 10.1097/PAS.0b013e3180321959.
• [9] Evaluating human cancer cell metastasis in zebrafish.BMC Cancer. 2013 Oct 4;13:453. doi: 10.1186/1471-2407-13-453.
• [10] Lysophosphatidic acid receptor-2 (LPA(2)) and LPA(5) regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2698-2703. doi: 10.1016/j.bbrc.2018.08.026. Epub 2018 Aug 7.
• [11] Lysophosphatidic acid receptor-5 negatively regulates cell motile and invasive activities of human sarcoma cell lines.Mol Cell Biochem. 2014 Aug;393(1-2):17-22. doi: 10.1007/s11010-014-2042-2. Epub 2014 Mar 28.
• [12] Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae.J Biomol Screen. 2011 Jan;16(1):44-52. doi: 10.1177/1087057110386371. Epub 2010 Dec 3.
• [13] Overexpression of a dominant negative CREB protein in HT-1080 cells selectively disrupts plasminogen activator inhibitor type 2 but not tissue-type plasminogen activator gene expression.FEBS Lett. 2000 Sep 29;482(1-2):75-80. doi: 10.1016/s0014-5793(00)02030-5.
• [14] IGF-I regulates HT1080 fibrosarcoma cell migration through a syndecan-2/Erk/ezrin signaling axis.Exp Cell Res. 2017 Dec 1;361(1):9-18. doi: 10.1016/j.yexcr.2017.09.035. Epub 2017 Sep 28.
• [15] miR-409-3p inhibits HT1080 cell proliferation, vascularization and metastasis by targeting angiogenin.Cancer Lett. 2012 Oct 28;323(2):171-9. doi: 10.1016/j.canlet.2012.04.010. Epub 2012 Apr 21.
• [16] Carboxypeptidase E promotes cancer cell survival, but inhibits migration and invasion.Cancer Lett. 2013 Dec 1;341(2):204-13. doi: 10.1016/j.canlet.2013.08.011. Epub 2013 Aug 11.
• [17] Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene.J Biol Chem. 2002 Oct 11;277(41):38456-61. doi: 10.1074/jbc.M203204200. Epub 2002 Aug 6.
• [18] Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance.Cancer Res. 2001 Jun 1;61(11):4599-604.
• [19] Cellular attachment to thrombospondin. Cooperative interactions between receptor systems.J Biol Chem. 1991 Jan 25;266(3):1740-5.
• [20] Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis.Cancer Res. 2010 Nov 15;70(22):9483-93. doi: 10.1158/0008-5472.CAN-09-3880. Epub 2010 Oct 26.
• [21] DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers.Cancer Res. 2003 Apr 15;63(8):1789-97.
• [22] LIM kinase-2 targeting as a possible anti-metastasis therapy.J Gene Med. 2004 Mar;6(3):357-63. doi: 10.1002/jgm.491.
• [23] Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1.Oncogene. 1997 Nov 13;15(20):2439-47. doi: 10.1038/sj.onc.1201421.
• [24] Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies.Br J Cancer. 1992 Feb;65(2):239-45. doi: 10.1038/bjc.1992.48.
• [25] Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.Cancer Res. 1997 Jul 15;57(14):2865-9.
• [26] The metal-responsive transcription factor-1 protein is elevated in human tumors.Cancer Biol Ther. 2010 Mar 15;9(6):469-76. doi: 10.4161/cbt.9.6.10979. Epub 2010 Mar 20.
• [27] Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma.J Surg Res. 2007 Jun 15;140(2):165-70. doi: 10.1016/j.jss.2006.11.018. Epub 2007 Apr 6.
• [28] Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms.Mod Pathol. 2019 Jul;32(7):1008-1022. doi: 10.1038/s41379-018-0184-6. Epub 2019 Mar 16.
• [29] A novel multiplexed, image-based approach to detect phenotypes that underlie chromosome instability in human cells.PLoS One. 2015 Apr 20;10(4):e0123200. doi: 10.1371/journal.pone.0123200. eCollection 2015.
• [30] Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules.Sci Rep. 2011;1:144. doi: 10.1038/srep00144. Epub 2011 Nov 7.
• [31] Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment.Cancer Res. 2000 May 15;60(10):2696-702.
• [32] SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.Cancer Res. 2012 Feb 1;72(3):810-20. doi: 10.1158/0008-5472.CAN-11-1052. Epub 2011 Dec 22.
• [33] Aberrant expression of BAFF receptor, a member of the tumor necrosis factor receptor family, in malignant cells of nonhematopoietic origins.Genes Cells. 2008 Oct;13(10):1061-73. doi: 10.1111/j.1365-2443.2008.01227.x. Epub 2008 Sep 3.
• [34] Immunohistochemical evaluation of mast cells and mark activity tryptase and chymase in experimental fibrosarcoma.Rocz Akad Med Bialymst. 2004;49 Suppl 1:61-3.
• [35] Requirements for sulfate transport and the diastrophic dysplasia sulfate transporter in fibronectin matrix assembly.J Cell Biol. 2007 Dec 3;179(5):999-1009. doi: 10.1083/jcb.200707150.
• [36] Loss of the dermis zinc transporter ZIP13 promotes the mildness of fibrosarcoma by inhibiting autophagy.Sci Rep. 2019 Oct 21;9(1):15042. doi: 10.1038/s41598-019-51438-9.
• [37] Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.J Endocrinol. 1999 Jun;161(3):455-64. doi: 10.1677/joe.0.1610455.
• [38] Easy detection of GFP-positive mutants following forward mutations at specific gene locus in cultured human cells.Mutat Res. 2011 Mar 18;721(1):101-7. doi: 10.1016/j.mrgentox.2010.12.010. Epub 2011 Jan 6.
• [39] Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence.J Biol Chem. 2007 Dec 14;282(50):36362-9. doi: 10.1074/jbc.M706301200. Epub 2007 Oct 9.
• [40] Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.Ann Diagn Pathol. 2015 Aug;19(4):221-5. doi: 10.1016/j.anndiagpath.2015.04.005. Epub 2015 May 6.
• [41] Glycogen synthase kinase 3 as a potential therapeutic target in synovial sarcoma and fibrosarcoma.Cancer Sci. 2020 Feb;111(2):429-440. doi: 10.1111/cas.14271. Epub 2019 Dec 30.
• [42] SLFN5 suppresses cancer cell migration and invasion by inhibiting MT1-MMP expression via AKT/GSK-3/-catenin pathway.Cell Signal. 2019 Jul;59:1-12. doi: 10.1016/j.cellsig.2019.03.004. Epub 2019 Mar 4.
• [43] The Roles of Sox Family Genes in Sarcoma.Curr Drug Targets. 2016;17(15):1761-1772. doi: 10.2174/1389450117666160502145311.
• [44] MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma.Oncol Rep. 2017 Aug;38(2):1199-1205. doi: 10.3892/or.2017.5774. Epub 2017 Jun 30.
• [45] CREG1 enhances p16(INK4a) -induced cellular senescence.Cell Cycle. 2011 Feb 1;10(3):518-30. doi: 10.4161/cc.10.3.14756. Epub 2011 Feb 1.
• [46] Elevated expression and altered processing of fibulin-1 protein in human breast cancer.Br J Cancer. 2003 Mar 24;88(6):871-8. doi: 10.1038/sj.bjc.6600802.
• [47] Human tissue factor pathway inhibitor-2 induces caspase-mediated apoptosis in a human fibrosarcoma cell line.Apoptosis. 2008 May;13(5):702-15. doi: 10.1007/s10495-008-0207-8.
• [48] Identifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis.Oncotarget. 2017 Oct 16;8(57):97231-97245. doi: 10.18632/oncotarget.21881. eCollection 2017 Nov 14.
• [49] CD97 inhibits cell migration in human fibrosarcoma cells by modulating TIMP-2/MT1- MMP/MMP-2 activity--role of GPS autoproteolysis and functional cooperation between the N- and C-terminal fragments.FEBS J. 2014 Nov;281(21):4878-91. doi: 10.1111/febs.13027. Epub 2014 Sep 22.
• [50] Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo.Cell Immunol. 2000 Mar 15;200(2):81-7. doi: 10.1006/cimm.2000.1622.
• [51] Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor.J Biol Chem. 1991 Jul 15;266(20):13442-8.
• [52] Angiopoietin-4 increases permeability of blood vessels and promotes lymphatic dilation.FASEB J. 2015 Sep;29(9):3668-77. doi: 10.1096/fj.14-268920. Epub 2015 May 14.
• [53] Proteomic Differences in Feline Fibrosarcomas Grown Using Doxorubicin-Sensitive and -Resistant Cell Lines in the Chick Embryo Model.Int J Mol Sci. 2018 Feb 14;19(2):576. doi: 10.3390/ijms19020576.
• [54] Arf6, JIP3, and dynein shape and mediate macropinocytosis.Mol Biol Cell. 2019 Jun 1;30(12):1477-1489. doi: 10.1091/mbc.E19-01-0022. Epub 2019 Apr 10.
• [55] Arfaptin 1 inhibits ADP-ribosylation factor-dependent matrix metalloproteinase-9 secretion induced by phorbol ester in HT 1080 fibrosarcoma cells.FEBS Lett. 2003 Feb 27;537(1-3):91-5. doi: 10.1016/s0014-5793(03)00098-x.
• [56] Similar regions of human chromosome 3 are eliminated from or retained in human/human and human/mouse microcell hybrids during tumor growth in severe combined immunodeficient (SCID) mice.Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1136-41. doi: 10.1073/pnas.98.3.1136.
• [57] Safety evaluation of a human chimeric monoclonal antibody that recognizes the extracellular loop domain of claudin-2.Eur J Pharm Sci. 2018 May 30;117:161-167. doi: 10.1016/j.ejps.2018.02.016. Epub 2018 Feb 13.
• [58] Cellular nucleic acid binding protein suppresses tumor cell metastasis and induces tumor cell death by downregulating heterogeneous ribonucleoprotein K in fibrosarcoma cells.Biochim Biophys Acta. 2014 Jul;1840(7):2244-52. doi: 10.1016/j.bbagen.2014.02.025. Epub 2014 Mar 2.
• [59] IFN- is required for cytotoxic T cell-dependent cancer genome immunoediting.Nat Commun. 2017 Feb 24;8:14607. doi: 10.1038/ncomms14607.
• [60] Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.Cancer Res. 2005 Oct 1;65(19):8878-86. doi: 10.1158/0008-5472.CAN-05-1479.
• [61] Contribution of Molecular Structure to Self-Assembling and Biological Properties of Bifunctional Lipid-Like 4-(N-Alkylpyridinium)-1,4-Dihydropyridines.Pharmaceutics. 2019 Mar 12;11(3):115. doi: 10.3390/pharmaceutics11030115.
• [62] Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma.Mod Pathol. 2017 Jun;30(6):884-891. doi: 10.1038/modpathol.2017.12. Epub 2017 Mar 3.
• [63] Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo.Cancer Res. 1995 Apr 15;55(8):1660-3.
• [64] Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays.Nutr Cancer. 2017 Feb-Mar;69(2):340-351. doi: 10.1080/01635581.2017.1263349. Epub 2017 Jan 3.
• [65] Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF.Cytokine. 1995 Jul;7(5):463-70. doi: 10.1006/cyto.1995.0063.
• [66] Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma.Cytotherapy. 2009;11(5):516-26. doi: 10.1080/14653240902960429.
• [67] Induction of early growth response-1 gene expression by calmodulin antagonist trifluoperazine through the activation of Elk-1 in human fibrosarcoma HT1080 cells.J Biol Chem. 2001 Mar 16;276(11):7797-805. doi: 10.1074/jbc.M009465200. Epub 2000 Dec 19.
• [68] Altered expression of ubiquitous kinesin heavy chain results in resistance to etoposide and hypersensitivity to colchicine: mapping of the domain associated with drug response.Cancer Res. 1998 Aug 1;58(15):3423-8.
• [69] A p27(kip1)-binding protein, p27RF-Rho, promotes cancer metastasis via activation of RhoA and RhoC.J Biol Chem. 2011 Jan 28;286(4):3139-48. doi: 10.1074/jbc.M110.159715. Epub 2010 Nov 17.
• [70] The identification of MAFB mutations in eight patients with multicentric carpo-tarsal osteolysis supports genetic homogeneity but clinical variability.Am J Med Genet A. 2013 Dec;161A(12):3023-9. doi: 10.1002/ajmg.a.36151. Epub 2013 Aug 16.
• [71] Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.Cancer Res. 2003 Nov 15;63(22):7936-41.
• [72] 58-kDa microspherule protein (MSP58) is novel Brahma-related gene 1 (BRG1)-associated protein that modulates p53/p21 senescence pathway.J Biol Chem. 2012 Jun 29;287(27):22533-48. doi: 10.1074/jbc.M111.335331. Epub 2012 May 4.
• [73] Identification and functional characterization of a novel human misshapen/Nck interacting kinase-related kinase, hMINK beta.J Biol Chem. 2004 Dec 24;279(52):54387-97. doi: 10.1074/jbc.M404497200. Epub 2004 Oct 6.
• [74] Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.J Clin Invest. 2012 Jan;122(1):241-52. doi: 10.1172/JCI58928. Epub 2011 Dec 1.
• [75] Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.J Biol Chem. 2010 May 21;285(21):16076-86. doi: 10.1074/jbc.M110.107094. Epub 2010 Mar 22.
• [76] Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53.Oncogene. 1997 Jan 23;14(3):359-67. doi: 10.1038/sj.onc.1200840.
• [77] Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon -1b.J Interferon Cytokine Res. 2015 Mar;35(3):186-99. doi: 10.1089/jir.2014.0115. Epub 2014 Oct 20.
• [78] Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.Nat Genet. 2010 Aug;42(8):715-21. doi: 10.1038/ng.619. Epub 2010 Jul 4.
• [79] Analysis of HIV type 1 reverse transcriptase expression in a human cell line.AIDS Res Hum Retroviruses. 1994 Sep;10(9):1117-24. doi: 10.1089/aid.1994.10.1117.
• [80] The interaction of the second Kunitz-type domain (KD2) of TFPI-2 with a novel interaction partner, prosaposin, mediates the inhibition of the invasion and migration of human fibrosarcoma cells.Biochem J. 2012 Jan 15;441(2):665-74. doi: 10.1042/BJ20110533.
• [81] Heterologous expression and characterization of the human R-ras gene product.Mol Cell Biol. 1987 Aug;7(8):2845-56. doi: 10.1128/mcb.7.8.2845-2856.1987.
• [82] hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation.Oncogene. 1999 Mar 4;18(9):1689-99. doi: 10.1038/sj.onc.1202469.
• [83] LUCA15, a putative tumour suppressor gene encoding an RNA-binding nuclear protein, is down-regulated in ras-transformed Rat-1 cells.Genes Cells. 2000 Oct;5(10):849-58. doi: 10.1046/j.1365-2443.2000.00370.x.
• [84] Identification of Small Molecule Translesion Synthesis Inhibitors That Target the Rev1-CT/RIR Protein-Protein Interaction.ACS Chem Biol. 2017 Jul 21;12(7):1903-1912. doi: 10.1021/acschembio.6b01144. Epub 2017 Jun 9.
• [85] Cmannosylation of Rspondin2 activates Wnt/catenin signaling and migration activity in human tumor cells.Int J Oncol. 2019 Jun;54(6):2127-2138. doi: 10.3892/ijo.2019.4767. Epub 2019 Apr 1.
• [86] Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.Eur J Pharmacol. 2005 Dec 19;527(1-3):31-6. doi: 10.1016/j.ejphar.2005.10.009. Epub 2005 Nov 23.
• [87] Purification and characterization of human lung fibroblast motility-stimulating factor for human soft tissue sarcoma cells: identification as an NH2-terminal fragment of human fibronectin.Cancer Res. 1997 Aug 15;57(16):3577-84.
• [88] Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition.Oncotarget. 2017 Apr 4;8(14):22685-22699. doi: 10.18632/oncotarget.15165.
• [89] COL1A2 is a TBX3 target that mediates its impact on fibrosarcoma and chondrosarcoma cell migration.Cancer Lett. 2019 Sep 10;459:227-239. doi: 10.1016/j.canlet.2019.06.004. Epub 2019 Jun 13.